Cardiovascular Events and Intensity of Treatment in Polycythemia Vera

Roberto Marchioli; Guido Finazzi; Giorgina Specchia; Rossella Cacciola; Riccardo Cavazzina; Daniela Cilloni; Valerio De Stefano; Elena Maria Elli; Alessandra Iurlo; Roberto Latagliata; Francesca Lunghi; Monia Lunghi; Rosa Maria Marfisi; Pellegrino Musto; Arianna Masciulli; Caterina Musolino; Nicola Cascavilla; Giovanni Quarta; Maria Luigia Randi; Davide Rapezzi; Marco Ruggeri; Elisa Rumi; Anna Rita Scortechini; Simone Santini; Marco Scarano; Sergio Siragusa; Antonio Spadea; Alessia Tieghi; Emanuele Angelucci; Giuseppe Visani; Alessandro Maria Vannucchi; Tiziano Barbui

doi:10.1056/nejmoa1208500

Key Points

To evaluate the effect of targeting a lower hematocrit level compared to a higher target on the incidence of cardiovascular death and major thrombotic events in patients with polycythemia vera.
Interventional clinical trial (ClinicalTrials.gov number NCT01645124, EudraCT number 2007-006694-91) conducted in patients diagnosed with polycythemia vera.
Compared two therapeutic intensity strategies targeting a hematocrit level of less than 45% versus a hematocrit level of 45% to 50%.
Patients treated to a target hematocrit below 45% experienced a significantly lower rate of cardiovascular death and major thrombosis compared with those treated to a target of 45% to 50%.

Abstract

In patients with polycythemia vera, those with a hematocrit target of less than 45% had a significantly lower rate of cardiovascular death and major thrombosis than did those with a hematocrit target of 45 to 50%. (Funded by the Italian Medicines Agency and others; ClinicalTrials.gov number, NCT01645124, and EudraCT number, 2007-006694-91.).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Marchioli et al. (2012) studied this question.

synapsesocial.com/papers/69d955ccc7f0c3ae80a3d078 https://doi.org/10.1056/nejmoa1208500

View Full Paper

Ask AI

Bookmark

Share

Cardiovascular Events and Intensity of Treatment in Polycythemia Vera

Key Points

Abstract

Discussion

Cite This Study

Cardiovascular Events and Intensity of Treatment in Polycythemia Vera

Key Points

Abstract

Discussion

Cite This Study

Keep reading

Keep reading